When I bought in 2019, the thesis was the same.
Low penetration of Life Insurance, a quality group and decent growth. But not much has played out since. Regulatory interventions have pulled it back often and VNB growth has been below expectations. Zero points for performance, 100 for my patience.
Subscribe To Our Free Newsletter |